A Randomized Phase II Study of Adebrelimab with Chemotherapy with or Without Bevacizumab as Neoadjuvant Therapy for Resectable Non-Squamous Non-Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating the safety and effectiveness of adebrelimab combined with chemotherapy, with or without bevacizumab, as a neoadjuvant treatment for adults aged 18 to 65 with resectable Stage II-IIIB non-squamous non-small cell lung cancer (NSQ-NSCLC). This Phase II, randomized, multicenter study aims to explore biomarkers linked to treatment response in this patient group. The trial is sponsored by The First Affiliated Hospital of Guangzhou Medical University and focuses on treatment before surgery to improve outcomes. Participants will receive either a combination of adebrelimab, chemotherapy, and bevacizumab or adebrelimab with chemotherapy alone. The chemotherapy regimens include paclitaxel, albuminotaxol, or docetaxel combined with platinum agents such as carboplatin, cisplatin, or nedaplatin, or pemetrexed combined with platinum. Treatment cycles last three weeks each, with a total of four cycles prior to surgical tumor removal. Surgery is scheduled 4 to 6 weeks after completing neoadjuvant therapy. During the study, participants undergo pathological response assessments within one week after surgery to measure treatment effects. Researchers will also monitor overall response rates before surgery and track event-free survival for up to 24 months. Safety follow-up will occur 30 days after the last bevacizumab or chemotherapy dose or 90 days after the last adebrelimab dose or surgery, whichever is later, to record any adverse events. The total study participation involves treatment, surgery, monitoring, and follow-up evaluations.

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC